Additional pharmacological analyses using the CellMiner Cross-Database (CellMiner CDB) (http://discover.nci.nih.gov/cellminercdb)29 showed that the activities of clinical TOP1 inhibitors (irinotecan and topotecan) and PEV are highly correlated across large panels of cancer cell lines (Supplementary Data Fig. 1e), implying TOP1 inhibitors with PEV as a potential therapy for cancers beyond CRC. Here, TOP1 is linked to colorectal carcinoma.